Metabolic & Cardiometabolic
Does ezetimibe treat the rare disease sitosterolemia?
The claim, precisely: ezetimibe treats sitosterolemia
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
RefutedContestedStrong support
consensus score 1.00
Yes, it blocks the plant-cholesterol over-absorption that defines the disease and is the treatment of choice.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 0 contradict 0 tested null 0 mixed · 4 sources, 4 independent groups
What the evidence shows
Ezetimibe is the drug of choice for sitosterolemia (ABCG5/G8 plant-sterol hyperabsorption) - it blocks the NPC1L1-mediated hyperabsorption that defines the disease. Its one definitive non-LDL indication. (Only relevant to [redacted].)
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mustajoki, et al. 2026 · (case) | observational | supports | moderate | Case data: ezetimibe (+rosuvastatin) corrected sitosterolemia dyslipidemia & lowered plant sterols |
| Lutjohann 2008 2008 · Int J Clin Pract | observational | supports | moderate | [FT-verified] 2yr open-label ext sitosterol -43.9% campesterol -50.8% apoB -10.1%; sustained |
| Salen 2004 · Circulation | RCT | supports | high | [FT-verified] Multicenter Sitosterolemia RCT n=37 4:1; Merck-funded COI; airtight NPC1L1 for disease-defining indication |
| Mustajoki, et al. 2026 · (case) | observational | supports | low | Case report homozygous ABCG8 phytosterolemia eze+rosuva+diet corrected dyslipidemia. n=1 |
| Othman 2014 · J Clin Lipidol | observational | supports | moderate | [FT-verified] Eze cut plant sterols + raised platelets/lowered MPV; consistent direction |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.